Solara Active Pharma Sciences Ltd
NSE: SOLARA BSE: 541540
₹425.55
(-3.87%)
Thu, 09 Apr 2026, 07:09 am
Market Cap20.48B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KSolara Active Pharma Sciences Analysis
dividend
- Solara Active Pharma Sciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Solara Active Pharma Sciences's dividends as it is not paying a notable one for India.
- Solara Active Pharma Sciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Solara Active Pharma Sciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Solara Active Pharma Sciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Solara Active Pharma Sciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Solara Active Pharma Sciences's earnings are expected to exceed the low risk growth rate next year.
- An improvement in Solara Active Pharma Sciences's performance (ROE) is expected over the next 3 years.
- Solara Active Pharma Sciences's revenue growth is expected to exceed the India market average.
- Solara Active Pharma Sciences's earnings are expected to grow by 11.3% yearly, however this is not considered high growth (20% yearly).
- Solara Active Pharma Sciences's earnings growth is positive but not above the India market average.
- Solara Active Pharma Sciences's net income is expected to increase but not above the 50% threshold in 2 years time.
- Solara Active Pharma Sciences is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
- Solara Active Pharma Sciences's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Solara Active Pharma Sciences's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).
health
- Solara Active Pharma Sciences is profitable, therefore cash runway is not a concern.
- Solara Active Pharma Sciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (41.6%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.1x debt.
- Solara Active Pharma Sciences's cash and other short term assets cover its long term commitments.
- Solara Active Pharma Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Interest payments on debt are not well covered by earnings (EBIT is 2.1x annual interest expense, ideally 3x coverage).
- Solara Active Pharma Sciences's level of debt (53.8%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- More shares have been bought than sold by Solara Active Pharma Sciences individual insiders in the past 3 months.
- The average tenure for the Solara Active Pharma Sciences board of directors is less than 3 years, this suggests a new board.
- The average tenure for the Solara Active Pharma Sciences management team is less than 2 years, this suggests a new team.
misc
- Solara Active Pharma Sciences is covered by less than 3 analysts.
- Solara Active Pharma Sciences has significant price volatility in the past 3 months.
past
- Solara Active Pharma Sciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Solara Active Pharma Sciences has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Solara Active Pharma Sciences's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (70.1% vs 22.7%).
- Solara Active Pharma Sciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Solara Active Pharma Sciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Solara Active Pharma Sciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Solara Active Pharma Sciences is good value based on assets compared to the IN Pharmaceuticals industry average.
- Solara Active Pharma Sciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
- SOLARA outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- SOLARA outperformed the Market in India which returned -14.5% over the past year.
- NSEI:SOLARA is up 23.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:SOLARA is up 23.3% outperforming the market in India which returned 8% over the past month.
- Solara Active Pharma Sciences is poor value based on expected growth next year.
- Solara Active Pharma Sciences is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800